Oragenics (NYSE:OGEN) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Friday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 8.3 %

Shares of Oragenics stock opened at $0.35 on Friday. Oragenics has a 12 month low of $0.35 and a 12 month high of $7.74. The firm has a market capitalization of $1.98 million, a P/E ratio of -0.05 and a beta of 0.45. The business’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $1.18.

Oragenics (NYSE:OGEN) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.